Dr Shah speaks with ecancertv at ASH 2016 about the first-in-human anti-CD22 CAR T-cell therapy.

She describes how therapies targetting CD19 results in diminished expression in many patients, opening the course of treatment for relapsed patients to novel targets, and that CD22 is a ubiquitous ligand with clinical utility.

Based on the results from this patient group, Dr Shah considers future therapies with bi-specific T cells aimed at both CD19 and CD22 for maximum impact.

More information is available in news coverage from ecancer here.

These results were presented by Dr Terry Fry, here, and discussed by Prof Armand Keating here.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.